Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study

BACKGROUND: Lipegfilgrastim has been shown to be non-inferior to pegfilgrastim for reduction of the duration of severe neutropenia (DSN) in breast cancer patients. This open-label, non-inferiority study assessed the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Link, Hartmut, Illerhaus, G., Martens, U. M., Salar, A., Depenbusch, R., Köhler, A., Engelhardt, M., Mahlmann, S., Zaiss, M., Lammerich, A., Bias, P., Buchner, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981320/
https://www.ncbi.nlm.nih.gov/pubmed/32944800
http://dx.doi.org/10.1007/s00520-020-05711-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981320/
https://www.ncbi.nlm.nih.gov/pubmed/32944800
http://dx.doi.org/10.1007/s00520-020-05711-7

Ejemplares similares